Clinical trials: Erythropoietin
Anemia
An Observational Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-myeloid Malignancy
This observational, prospective, multicenter study will evaluate the treatment response rate and the safety of NeoRecormon (epoetin beta) in anemic patients with non-myeloid malignancy.
- Trial name
- NCT01716559
- Where
- 6 sites in Hungary
- Volunteers
- 160 people
- Sponsor
- Hoffmann-La Roche
Anemia, Kidney Diseases
Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.
The purpose of this study is to evaluate the hemoglobin response rate in subjects with anemia, associated with chronic kidney failure, after receiving epoetin alfa (PROCRIT®) every 2 weeks
- Trial name
- NCT00210743
- Testing
- epoetin alfa
- Volunteers
- 67 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Renal Anemia
Study to Compare the Safety and Efficacy of UB-851 and Eprex®
The primary objective of this study is to evaluate a 1:1 dose conversion from Eprex® to UB-851 in terms of clinical efficacy and safety in subjects with chronic renal failure receiving hemodialysis.
- Trial name
- NCT02708914
- Testing
- UB-851, Eprex
- Volunteers
- 269 people
- Sponsor
- UBI Pharma Inc.
HIV Infections, Cytopenias
Treatment Program for Anemia in AIDS Patients
The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.
- Trial name
- NCT00002022
- Testing
- Epoetin alfa
- Where
- United States
- Sponsor
- R W Johnson Pharmaceutical Research Institute
Chronic Kidney Disease
HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney disease (CKD)
- Trial name
- SENSE (NCT01576341)
- Testing
- HX575 epoetin alfa (Sandoz)
- Where
- 50 sites in Germany, Italy and 5 more
- Volunteers
- 417 people
- Sponsor
- Sandoz
Anemia
Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy
To assess the change in hemoglobin levels when iron sucrose was added to a regimen of weekly, fixed doses of erythropoietin in patients who had or had not responded to erythropoietin therapy alone.
- Trial name
- NCT00236951
- Testing
- iron sucrose injection USP, stable erythropoietin therapy
- Volunteers
- 224 people
- Sponsor
- American Regent, Inc.
Anemia, HIV Infections
An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)
The objective of this study was to treat anemic (Hemoglobin (Hb) < 12 g/dL) HIV-infected subjects with once weekly (QW) PROCRIT (Epoetin alfa) to a target Hb of > 13 g/dL and then to assess if the target Hb level and improvements…
- Trial name
- NCT00317902
- Testing
- Epoetin alfa
- Volunteers
- 292 people
- Sponsor
- Ortho Biotech Products, L.P.
Parkinson Disease
Safety Study of Erythropoietin (EPO) in Parkinson's Disease
The purpose of this study is to determine whether recombinant human Erythropoietin (EPOrh) is safe in the treatment of patients with Parkinson's Disease.
- Trial name
- NCT01010802
- Testing
- Erythropoietin human recombinant (EPOrh)
- Where
- Cuba
- Volunteers
- 10 people
- Sponsor
- International Center for Neurological Restoration, Cuba
Anemia
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
This study will assess the comfort of subcutaneous injections of NeoRecormon and darbepoetin alfa (Aranesp) in patients with renal anemia.
- Trial name
- NCT00377481
- Testing
- darbepoetin alfa, epoetin beta [NeoRecormon]
- Where
- 8 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Anemia, Acute Myeloid Leukemia
Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy
Anemia concerns a lot of patients with cancer and affects their quality of life (QOL). Numerous studies in oncology have demonstrated the benefit of erythropoiesis-stimulating agents (ESA) in the treatment of anemia.
- Trial name
- EPREX/LAM-ALLO (NCT02860598)
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Hospices Civils de Lyon
Anemia, Kidney Failure
Dynepo Infrequent Dosing Study
The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as measured by haemoglobin at week 24 and…
- Trial name
- NCT00450333
- Testing
- Dynepo (Epoetin delta), Dynepo
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 407 people
- Sponsor
- Shire
Anemia Renal
Pentoxifylline Administration in Hemodialysis Patients
The aim of the study is to assess the impact of pentoxifylline administration on the modulation of hyporesponsiveness to erythropoietin stimulating agents in hemodialysis patients
- Trial name
- NCT03800433
- Testing
- Trental 400 MG Extended Release Oral Tablet
- Volunteers
- 46 people
- Sponsor
- Ain Shams University
Chronic Renal Failure, Chronic Kidney Disease
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
The purpose of the study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- EMERALD 1 (NCT00597753)
- Testing
- peginesatide, Epoetin Alfa
- Where
- 89 sites in United States
- Volunteers
- 803 people
- Sponsor
- Affymax
Myocardial Infarction, Angioplasty, Transluminal, Percutaneous Coronary
Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)
The purpose of this study is to determine whether erythropoietin is superior to placebo with respect to left ventricular ejection fraction in patients with ST-elevation myocardial infarction undergoing percutaneous coronary…
- Trial name
- REVIVAL-3 (NCT00390832)
- Testing
- Erythropoietin
- Where
- 2 sites in Germany
- Volunteers
- 138 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Renal Anemia of Chronic Kidney Disease
A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease
The purpose of this study is to evaluate the effectiveness and safety of YPEG rhEPO, a recombinant human erythropoietin pegylated by Y shape polyethylene glycol, in patients with anemia due to Chronic Kidney Disease (CKD)…
- Trial name
- NCT04885647
- Testing
- YPEG-rhEPO
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Anemia
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
Pharmacokinetic/Pharmacodynamic Study of 3 Epoetin Alfa Formulations in Single Subcutaneous Doses Administered to Healthy Volunteers SPONSOR Biosidus S.A.
- Trial name
- NCT03822884
- Testing
- Epoetin Alfa 40000 UNT/ML
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bio Sidus SA
Conjunctival and Scleral Avascular Lesions
The Effect of Erythropoietin in the Treatment of Scleral Necrosis
Patients with acute avascular lesions of the conjunctiva and sclera will be included in the study. Patients will undergo a complete eye examination including a slit lamp, intraocular pressure measurement, and fundoscopy with…
- Trial name
- NCT05476042
- Testing
- Erythropoietin prescription
- Where
- Iran
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Anemia, Kidney Transplantation
An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant
This observational study will investigate efficacy and safety of methoxy polyethyleneglycol-epoetin beta in participants with a kidney transplant. Data of each participant will be collected over 15 months of Mircera therapy.
- Trial name
- NCT02538107
- Testing
- Methoxy-polyethyleneglycol epoetin beta
- Where
- Germany
- Volunteers
- 290 people
- Sponsor
- Hoffmann-La Roche
Anemia, Leukemia
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00255749
- Testing
- epoetin alfa
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Anemia, Cancer
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
The purpose of this study is to evaluate the hematologic response, safety, and clinical outcomes of PROCRIT administered once a week in anemic cancer patients receiving chemotherapy.
- Conditions
- Anemia, Cancer, Chemotherapy
- Trial name
- NCT00341055
- Testing
- Epoetin alfa
- Volunteers
- 69 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.